TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Wednesday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $9.04 million for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $8.26 million during the quarter, compared to analysts’ expectations of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

TLSI opened at $5.07 on Wednesday. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.24. The stock has a market capitalization of $163.62 million, a price-to-earnings ratio of -2.04 and a beta of 0.50. The business has a fifty day moving average price of $5.40 and a 200 day moving average price of $4.98.

Analyst Ratings Changes

Several research analysts recently commented on the company. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Roth Mkm reissued a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Finally, Lake Street Capital assumed coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They set a “buy” rating and a $10.00 target price for the company. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.93.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.